This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
There’s no shortage of resources for healthcare workers who wish they knew AI well enough to talk shop with the technology pros who develop the models. The problem is weeding through the offerings to get to what will really work for you.
Discussions of AI governance may cause many an eye to glass over, but the discipline is as crucial to the ascent of AI in healthcare as big training datasets drawn from diverse patient populations.
For whatever reason, the grownups seem to get all the attention when talk turns to AI in healthcare. All the kiddos get to do is look on and listen in. Now comes a worthy little effort to balance the seesaw.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
“Until there is a global consensus on how this is regulated, Asian countries—where data privacy is less of a focus—could see a clear contrast with the West in how AI is used.”
The American Hospital Association is sounding the alarm over evidently widespread acceptance of 0% operating margins—or even negative margins—as a sort of “new normal” for U.S. hospitals and health systems.
U.S. News & World Report has posted its annual list of America’s best hospitals. But be warned. If you’re checking to see whether Mayo Clinic occupies the overall top spot for the eighth straight year, you’ll go down looking.
Physicians whose personality traits include maladaptive perfectionism are at increased risk of depression and suicidal ideation compared with peers who don’t bear this type of neurosis.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.